Researchers assessed 55 first-episode drug-naive people with schizophrenia diagnoses in New Delhi, India for the predictive value of symptoms on quality of life (QOL). They found that negative symptoms have a greater impact than positive on subjective quality of life, while antipsychotics focus on primary positive and negative symptoms. “There is a need to develop a holistic approach (target non-psychotic symptoms intensively) in the disease management to prevent further long-term impairment of QOL.” The study appears in the Nordic Journal of Psychiatry.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.